Showing results (311-320 of 336) with videos related to
Sort By:
Pageof 34
British Journal of Cancer|July 16, 2025
Single-cell spatial analysis with Xenium reveals anti-tumour responses of CXCL13 + T and CXCL9+ cells after radiotherapy combined with anti-PD-L1 therapyShunsuke A Sakai, Hidekazu Oyoshi, Masaki Nakamura, et al.Cancer Science|February 2, 2026
Analysis of Peripheral T Cell Profiling and Plasma Proteomics in Advanced NSCLC Patients Treated With AtezolizumabAtsuto Mouri, Hiroshi Kagamu, Koji Tamada, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 28, 2016
The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016Daniel S W Tan, Sue S Yom, Ming S Tsao, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 20, 2024
Neoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung CancerJonathan D Spicer, Tina Cascone, Murry W Wynes, et al.Respiratory Research|July 25, 2016
A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study)Takekazu Iwata, Ichiro Yoshino, Shigetoshi Yoshida, et al.Cancer Science|September 28, 2022
High levels of AXL expression in untreated EGFR-mutated non-small cell lung cancer negatively impacts the use of osimertinibAkihiro Yoshimura, Tadaaki Yamada, Masakuni Serizawa, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 22, 2025
Surgical Outcomes With Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLCTetsuya Mitsudomi, John V Heymach, Martin Reck, et al.The New England Journal of Medicine|October 23, 2023
Perioperative Durvalumab for Resectable Non-Small-Cell Lung CancerJohn V Heymach, David Harpole, Tetsuya Mitsudomi, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 11, 2021
Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung CancerChristian Rolfo, Philip Mack, Giorgio V Scagliotti, et al.The New England Journal of Medicine|June 2, 2025
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung CancerPatrick M Forde, Jonathan D Spicer, Mariano Provencio, et al.Pageof 34